Omid Hamid, Robert Ilaria Jr, Claus Garbe, Pascal Wolter, Michele Maio, Thomas E. Hutson, Ana Arance, Paul Lorigan, Jeeyun Lee, Axel Hauschild, Peter Mohr, Marjo Hahka-Kemppinen, Christopher Kaiser, P. Kellie Turner, Ilaria Conti and Jean-Jacques Grob A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma Cancer 120
Article first published online: 26 MAR 2014 | DOI: 10.1002/cncr.28635
The current phase 3 melanoma trial demonstrated greater hematologic toxicity in the group of patients treated with tasisulam compared with those receiving paclitaxel, which was attributed to low tasisulam clearance in a subset of patients. These results underscore the importance of pharmacokinetic monitoring of compounds with complex dosing, even in late-phase studies.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field